HRP20210406T1 - Postupci za povećanje volumena prisilnog izdisaja kod astmatičara uporabom benralizumaba - Google Patents
Postupci za povećanje volumena prisilnog izdisaja kod astmatičara uporabom benralizumaba Download PDFInfo
- Publication number
- HRP20210406T1 HRP20210406T1 HRP20210406TT HRP20210406T HRP20210406T1 HR P20210406 T1 HRP20210406 T1 HR P20210406T1 HR P20210406T T HRP20210406T T HR P20210406TT HR P20210406 T HRP20210406 T HR P20210406T HR P20210406 T1 HRP20210406 T1 HR P20210406T1
- Authority
- HR
- Croatia
- Prior art keywords
- benralizumab
- use according
- patient
- optionally
- administration
- Prior art date
Links
- 229950000321 benralizumab Drugs 0.000 title claims 20
- 208000006673 asthma Diseases 0.000 title claims 6
- 230000005713 exacerbation Effects 0.000 claims 5
- 229940125369 inhaled corticosteroids Drugs 0.000 claims 2
- PZSMUPGANZGPBF-UHFFFAOYSA-N 4-[5-(dithiolan-3-yl)pentanoylamino]butanoic acid Chemical compound OC(=O)CCCNC(=O)CCCCC1CCSS1 PZSMUPGANZGPBF-UHFFFAOYSA-N 0.000 claims 1
- 210000004027 cell Anatomy 0.000 claims 1
- 239000003246 corticosteroid Substances 0.000 claims 1
- 210000003979 eosinophil Anatomy 0.000 claims 1
- 229940127212 long-acting beta 2 agonist Drugs 0.000 claims 1
- 229940125389 long-acting beta agonist Drugs 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Biomedical Technology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Endocrinology (AREA)
Claims (12)
1. Učinkovita količina benralizumaba za upotrebu u postupku liječenja astme povećanjem volumena prisilnog izdisaja u jednoj sekundi (FEV1) kod pacijenta s astmom, pri čemu primjena povećava pacijentov FEV1, naznačen time što se benralizumab primjenjuje u dozi od 30 mg svaka četiri tjedna.
2. Benralizumab za uporabu prema zahtjevu 1, naznačen time što je astma eozinofilna astma.
3. Benralizumab za uporabu prema bilo kojem od patentnih zahtjeva 1 ili 2, naznačen time što pacijent ima broj eozinofila u krvi od najmanje 300 stanica/µl.
4. Benralizumab za uporabu prema bilo kojem od patentnih zahtjeva 1-3, naznačen time što pacijent ima prisilan volumen izdisaja u jednoj sekundi (FEV1) od najmanje 75% predviđene vrijednosti prije primjene.
5. Benralizumab za uporabu prema bilo kojem od patentnih zahtjeva 1-4, naznačen time što pacijent ima rezultat kontrolnog upitnika za astmu od najmanje 1.5 prije primjene.
6. Benralizumab za uporabu prema bilo kojem od patentnih zahtjeva 1-5, naznačen time što povećava pacijentov FEV1 nakon primjene benralizumaba.
7. Benralizumab za uporabu prema bilo kojem od patentnih zahtjeva 1-6, naznačen time što se FEV1 povećava za najmanje 0.1 L, po izboru za najmanje 0.13 L, po izboru za najmanje 0.2 L, po izboru za najmanje 0.25 L, po izboru za najmanje 0.5 L.
8. Benralizumab za uporabu prema bilo kojem od patentnih zahtjeva 1-7, naznačen time što pacijent koristi visoku dozu inhalacijskih kortikosteroida (ICS).
9. Benralizumab za uporabu prema bilo kojem od patentnih zahtjeva 1-8, naznačen time što pacijent koristi dugodjelujuće β2 agoniste (LABA).
10. Benralizumab za uporabu prema bilo kojem od patentnih zahtjeva 1-9, naznačen time što pacijent ima povijest egzacerbacija, po izboru pri čemu povijest egzacerbacija obuhvaća barem dvije egzacerbacije godišnje prije primjene benralizumaba, po izboru pri čemu povijest egzacerbacija obuhvaća ne više od šest egzacerbacija godišnje prije primjene benralizumaba.
11. Benralizumab za uporabu prema bilo kojem od patentnih zahtjeva 1-10, naznačen time što se benralizumab primjenjuje parenteralno, po izboru pri čemu se benralizumab primjenjuje potkožno.
12. Benralizumab za uporabu prema bilo kojem od patentnih zahtjeva 1-11, naznačen time što se benralizumab primjenjuje uz terapiju kortikosteroidima.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361864948P | 2013-08-12 | 2013-08-12 | |
| EP19158446.5A EP3520811B1 (en) | 2013-08-12 | 2014-08-07 | Methods for increasing forced expiratory volume in asthmatics using benralizumab |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20210406T1 true HRP20210406T1 (hr) | 2021-04-30 |
Family
ID=52448838
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20190920TT HRP20190920T1 (hr) | 2013-08-12 | 2019-05-17 | Postupci za povećanje volumena prisilnog izdisaja kod astmatičara uporabom benralizumaba |
| HRP20210406TT HRP20210406T1 (hr) | 2013-08-12 | 2021-03-10 | Postupci za povećanje volumena prisilnog izdisaja kod astmatičara uporabom benralizumaba |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20190920TT HRP20190920T1 (hr) | 2013-08-12 | 2019-05-17 | Postupci za povećanje volumena prisilnog izdisaja kod astmatičara uporabom benralizumaba |
Country Status (25)
| Country | Link |
|---|---|
| US (1) | US9441046B2 (hr) |
| EP (3) | EP3875487A1 (hr) |
| JP (3) | JP6746496B2 (hr) |
| KR (1) | KR102337599B1 (hr) |
| CN (2) | CN105451769A (hr) |
| AU (2) | AU2014306959B2 (hr) |
| BR (1) | BR112016002317A8 (hr) |
| CA (1) | CA2917603C (hr) |
| CY (2) | CY1122033T1 (hr) |
| DK (2) | DK3033104T3 (hr) |
| ES (2) | ES2733602T3 (hr) |
| HK (2) | HK1222559A1 (hr) |
| HR (2) | HRP20190920T1 (hr) |
| HU (2) | HUE043497T2 (hr) |
| LT (2) | LT3520811T (hr) |
| ME (1) | ME03403B (hr) |
| MX (2) | MX2016001384A (hr) |
| PL (2) | PL3033104T3 (hr) |
| PT (2) | PT3520811T (hr) |
| RS (2) | RS61565B1 (hr) |
| RU (1) | RU2703568C2 (hr) |
| SG (1) | SG11201600483QA (hr) |
| SI (2) | SI3520811T1 (hr) |
| TR (1) | TR201907907T4 (hr) |
| WO (1) | WO2015023507A2 (hr) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2728578C2 (ru) | 2013-08-12 | 2020-07-30 | Астразенека Аб | Способы нормализации симптомов астмы с применением бенрализумаба |
| CN111588848A (zh) * | 2013-08-12 | 2020-08-28 | 阿斯特拉捷利康股份公司 | 使用贝那利珠单抗降低哮喘恶化率的方法 |
| BR112016008082A2 (pt) * | 2013-10-15 | 2017-10-17 | Medimmune Llc | métodos para tratamento de doença pulmonar obstrutiva crônica usando benralizumab |
| MX2016004605A (es) * | 2013-10-24 | 2016-11-14 | Astrazeneca Ab | Formulaciones de anticuerpos estables acuosas. |
| TW202110479A (zh) * | 2019-05-16 | 2021-03-16 | 瑞典商阿斯特捷利康公司 | 使用貝那利珠單抗治療增強型患者群體慢性阻塞性肺病之方法 |
| TW202214692A (zh) * | 2020-06-05 | 2022-04-16 | 瑞典商阿斯特捷利康公司 | 治療患有鼻瘜肉的患者的重度氣喘之方法 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2233974T3 (es) | 1995-09-11 | 2005-06-16 | Kyowa Hakko Kogyo Co., Ltd. | Anticuerpo contra la cadena alfa del receptor de la interleucina 5 humana. |
| US6746839B1 (en) * | 1998-01-12 | 2004-06-08 | Interleukin Genetics, Inc. | Diagnostics and therapeutics for an obstructive airway disease |
| EP2264166B1 (en) | 1999-04-09 | 2016-03-23 | Kyowa Hakko Kirin Co., Ltd. | Method for controlling the activity of immunologically functional molecule |
| EP1266663A4 (en) | 2000-02-15 | 2003-07-23 | Kyowa Hakko Kogyo Kk | EOSINOPHILE SPECIFIC APOPTOSE INDUCTORS |
| US6946292B2 (en) | 2000-10-06 | 2005-09-20 | Kyowa Hakko Kogyo Co., Ltd. | Cells producing antibody compositions with increased antibody dependent cytotoxic activity |
| US8093357B2 (en) | 2002-03-01 | 2012-01-10 | Xencor, Inc. | Optimized Fc variants and methods for their generation |
| EP1688437A4 (en) | 2003-10-08 | 2007-09-26 | Kyowa Hakko Kogyo Kk | SPECIALLY BINDING ANTIBODY COMPOSITION TO IL-5 RECEPTOR |
| US20060014680A1 (en) | 2004-07-13 | 2006-01-19 | Caiding Xu | Peptides and compounds that bind to the IL-5 receptor |
| AU2006299429B2 (en) | 2005-10-03 | 2012-02-23 | Xencor, Inc. | Fc variants with optimized Fc receptor binding properties |
| MX2020011303A (es) * | 2007-05-14 | 2021-12-17 | Astrazeneca Ab | Metodos para reducir niveles de eosinofilos. |
| RU2383345C1 (ru) * | 2008-08-07 | 2010-03-10 | Государственное образовательное учреждение высшего профессионального образования "Нижегородская государственная медицинская академия Росздрава" (ГОУ ВПО "НИЖГМА РОСЗДРАВА") | Способ лечения больных бронхиальной астмой |
| EP3447491A3 (en) * | 2010-12-16 | 2019-06-05 | F. Hoffmann-La Roche AG | Diagnosis and treatments relating to th2 inhibition |
| CN102544908B (zh) | 2010-12-17 | 2016-01-06 | 富士康(昆山)电脑接插件有限公司 | 电连接器组件及插头连接器 |
| WO2012158954A1 (en) * | 2011-05-18 | 2012-11-22 | Medimmune, Llc | Methods of diagnosing and treating pulmonary diseases or disorders |
| AU2012332859A1 (en) * | 2011-11-01 | 2014-05-22 | Medimmune, Llc | Methods for reducing the frequency and severity of acute exacerbations of asthma |
| RU2728578C2 (ru) | 2013-08-12 | 2020-07-30 | Астразенека Аб | Способы нормализации симптомов астмы с применением бенрализумаба |
| CN111588848A (zh) * | 2013-08-12 | 2020-08-28 | 阿斯特拉捷利康股份公司 | 使用贝那利珠单抗降低哮喘恶化率的方法 |
-
2014
- 2014-08-07 TR TR2019/07907T patent/TR201907907T4/tr unknown
- 2014-08-07 CN CN201480045047.8A patent/CN105451769A/zh active Pending
- 2014-08-07 ME MEP-2019-137A patent/ME03403B/me unknown
- 2014-08-07 WO PCT/US2014/050119 patent/WO2015023507A2/en active Application Filing
- 2014-08-07 SI SI201431795T patent/SI3520811T1/sl unknown
- 2014-08-07 HU HUE14836725A patent/HUE043497T2/hu unknown
- 2014-08-07 SG SG11201600483QA patent/SG11201600483QA/en unknown
- 2014-08-07 PL PL14836725T patent/PL3033104T3/pl unknown
- 2014-08-07 HU HUE19158446A patent/HUE053627T2/hu unknown
- 2014-08-07 LT LTEP19158446.5T patent/LT3520811T/lt unknown
- 2014-08-07 DK DK14836725.3T patent/DK3033104T3/da active
- 2014-08-07 EP EP20208316.8A patent/EP3875487A1/en active Pending
- 2014-08-07 RS RS20210305A patent/RS61565B1/sr unknown
- 2014-08-07 US US14/454,138 patent/US9441046B2/en active Active
- 2014-08-07 PT PT191584465T patent/PT3520811T/pt unknown
- 2014-08-07 RU RU2016108809A patent/RU2703568C2/ru active
- 2014-08-07 EP EP14836725.3A patent/EP3033104B1/en active Active
- 2014-08-07 AU AU2014306959A patent/AU2014306959B2/en active Active
- 2014-08-07 ES ES14836725T patent/ES2733602T3/es active Active
- 2014-08-07 CN CN202010450690.6A patent/CN111588849A/zh active Pending
- 2014-08-07 KR KR1020167006576A patent/KR102337599B1/ko active IP Right Grant
- 2014-08-07 MX MX2016001384A patent/MX2016001384A/es unknown
- 2014-08-07 EP EP19158446.5A patent/EP3520811B1/en active Active
- 2014-08-07 BR BR112016002317A patent/BR112016002317A8/pt not_active Application Discontinuation
- 2014-08-07 PT PT14836725T patent/PT3033104T/pt unknown
- 2014-08-07 DK DK19158446.5T patent/DK3520811T3/da active
- 2014-08-07 RS RS20190556A patent/RS58711B1/sr unknown
- 2014-08-07 PL PL19158446T patent/PL3520811T3/pl unknown
- 2014-08-07 JP JP2016534615A patent/JP6746496B2/ja active Active
- 2014-08-07 CA CA2917603A patent/CA2917603C/en active Active
- 2014-08-07 ES ES19158446T patent/ES2866426T3/es active Active
- 2014-08-07 LT LTEP14836725.3T patent/LT3033104T/lt unknown
- 2014-08-07 SI SI201431191T patent/SI3033104T1/sl unknown
-
2016
- 2016-01-29 MX MX2021003826A patent/MX2021003826A/es unknown
- 2016-09-12 HK HK16110776.1A patent/HK1222559A1/zh unknown
- 2016-12-01 HK HK16113676A patent/HK1225300A1/zh unknown
-
2019
- 2019-05-17 HR HRP20190920TT patent/HRP20190920T1/hr unknown
- 2019-07-03 CY CY20191100700T patent/CY1122033T1/el unknown
-
2020
- 2020-02-21 AU AU2020201277A patent/AU2020201277A1/en not_active Abandoned
- 2020-04-03 JP JP2020067766A patent/JP2020125304A/ja not_active Withdrawn
-
2021
- 2021-03-10 HR HRP20210406TT patent/HRP20210406T1/hr unknown
- 2021-03-24 CY CY20211100261T patent/CY1124399T1/el unknown
-
2022
- 2022-06-07 JP JP2022092222A patent/JP2022120010A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20210406T1 (hr) | Postupci za povećanje volumena prisilnog izdisaja kod astmatičara uporabom benralizumaba | |
| BR112015027282A2 (pt) | fenfluramina para uso no tratamento de síndrome de dravet | |
| PH12015501404A1 (en) | Neuroactive 19-alkoxy-17-substituted steroids, prodrugs thereof, and methods of treatment using same | |
| WO2015085143A3 (en) | Therapeutic agents for skin diseases and conditions | |
| CR20160278A (es) | Nuevas indazolcarboxamidas, procedimientos para su preparación, preparaciones farmacéuticas que las contienen, asi como su uso para la preparación de medicamentos | |
| NZ712350A (en) | Abiraterone acetate formulation | |
| HRP20220978T1 (hr) | Upotreba oksidiranih kolesterol sulfata (ocs) za liječenje disfunkcije bubrega | |
| EA033113B1 (ru) | Способы лечения аутоиммунных, респираторных и воспалительных расстройств ингаляцией n-оксида рофлумиласта | |
| MX2014002171A (es) | Tratamientos de combinacion para hepatitis c. | |
| AR097619A1 (es) | Uso de inhibidores de acetil-coa carboxilasa para tratar acné vulgaris | |
| WO2015099838A3 (en) | Compositions and methods of treating ocular diseases | |
| MD20150120A2 (ro) | Tratamentul bolilor neurodegenerative şi miopatice de agregare proteică prin administrarea parenterală a trehalozei | |
| BR112015024621A2 (pt) | c. novyi para o tratamento de tumores sólidos em seres humanos | |
| WO2016044839A3 (en) | Compositions and methods for treating viral infections through stimulated innate immunity in combination with antiviral compounds | |
| BR112018000383A2 (pt) | métodos para tratar hcv | |
| AR091161A1 (es) | Composicion farmaceutica para inhalacion, metodo, uso | |
| JP2014520874A5 (hr) | ||
| MX2015009891A (es) | Composiciones farmaceuticas que comprenden particulas cristalinas de multicomponentes adecuadas para usar en terapia de inhalacion. | |
| CL2015002627A1 (es) | Composiciones para el uso en el tratamiento de trastornos oculares que usan dipiridamol | |
| MX2015011347A (es) | Tratamiento sistemico y topico combinado de tejidos con trastorno. | |
| BR112015019524A2 (pt) | tratamento de combinação | |
| WO2014018763A3 (en) | Method of treating type i diabetes using apolipoprotein aiv | |
| BR112014018426A8 (pt) | Composição e dispositivo para administração transdérmica, e, método para administrar uma progestina | |
| EA201592261A1 (ru) | Фармацевтические композиции, включающие агомелатин в форме сокристаллов агомелатина с органической кислотой | |
| WO2014122537A3 (en) | Pharmaceutical compositions and methods of treating hepatitis c virus infection using a combination of hydroxychloroquine and ribavirin |